Search

Displaying results 4961 - 4970 of 9670 in total
  1. Drug

    Tilarginine

    go.drugbank.com/drugs/DB11815
    ApprovedInvestigationalWithdrawn

    Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

  2. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.

  3. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying. … Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies,

  4. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

  5. Drug

    Lauric acid

    go.drugbank.com/drugs/DB03017
    Approved

    Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.

  6. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

  7. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7. … It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation.

  8. Drug

    Loprazolam

    go.drugbank.com/drugs/DB13643
    Experimental

    It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. It is not an FDA-approved drug. … Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms.

  9. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    In clinical trials, it has shown significant efficacy and safety compared to a placebo. … Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as serious adverse events and injection reactions such as fever and chills have been reported.

  10. Drug

    MX6

    go.drugbank.com/drugs/DB05789
    Experimental

    More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and … 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias